CLINICAL_TRIALS
trial_result
· 2026-03-16
Clinical Trial Update: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease [Phase 3]
Summary
A Phase 3 study of subcutaneously administered efgartigimod for Thyroid Eye Disease has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: argenx | Conditions: Thyroid Eye Disease | Phase 3 | Status: TERMINATED